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Engraftment and maintenance of hematopoietic stem and pro-
genitor cells (HSPC) depend on their ability to respond to extra-
cellular signals from the bone marrow microenvironment, but the
critical intracellular pathways integrating these signals remain
poorly understood. Furthermore, recent studies provide contradic-
tory evidence of the roles of vascular versus osteoblastic niche
components in HSPC function. To address these questions and to
dissect the complex upstream regulation of Rac GTPase activity
in HSPC, we investigated the role of the hematopoietic-speciﬁc
guanine nucleotide exchange factor Vav1 in HSPC localization
and engraftment. Using intravital microscopy assays, we demon-
strated that transplanted Vav1
−/− HSPC showed impaired early lo-
calization near nestin
+ perivascular mesenchymal stem cells; only
6.25% of Vav1
−/− HSPC versus 45.8% of wild-type HSPC were lo-
cated less than 30 μm from a nestin
+ cell. Abnormal perivascular
localization correlated with decreased retention of Vav1
−/− HSPC
in the bone marrow (44–60% reduction at 48 h posttransplant,
compared with wild-type) and a very signiﬁcant defect in short-
and long-term engraftment in competitive and noncompetitive re-
population assays (<1.5% chimerism of Vav1
−/− cells vs. 53–63%
for wild-type cells). The engraftment defect of Vav1
−/− HSPC was
not related to alterations in proliferation, survival, or integrin-
mediated adhesion. However, Vav1
−/− HSPC showed impaired
responses to SDF1α, including reduced in vitro migration in time-
lapse microscopy assays, decreased circadian and pharmacologi-
cally induced mobilization in vivo, and dysregulated Rac/Cdc42
activation. These data suggest that Vav1 activity is required specif-
ically for SDF1α-dependent perivascular homing of HSPC and sug-
gest a critical role for this localization in retention and subsequent
engraftment.
H
ematopoietic stem cells (HSC) are deﬁned by their ability to
self-renew and the potential to generate all mature hema-
topoietic lineages, both during homeostasis and after transplan-
tation. Maintenance of these functions critically depends on
the interaction of HSC with one or several specialized micro-
environments (so-called niches) in the bone marrow (BM) (1).
Different cell populations have been proposed to form niches
for HSC, including osteoblasts (2, 3), endothelial cells (4), stro-
mal-derived factor-1 alpha (SDF1α)-expressing reticular cells
(5), and nestin
+ mesenchymal stem cells (MSC) (6). These com-
ponents appear to be spatially related in the BM (5–7), but it
is not clear whether they constitute a number of functionally
distinct HSC niches or contribute to a complex multicellular
hematopoietic microenvironment, and, speciﬁcally, there is con-
ﬂicting evidence on the relative roles of osteoblastic versus vas-
cular components of the niche in regulating hematopoietic stem
and progenitor cell (HSPC) functions. Extracellular cues pro-
posed to play a decisive role in hematopoietic stem/progenitor
cell interaction with and retention in the niche include stem cell
factor (SCF), concentration gradients of the chemoattractant
CXCL12/SDF1α, and β1 integrin-mediated adhesion to extra-
cellular matrix and VCAM1
+ endothelium (8–12).
The crucial intracellular pathways triggered by these signals
are less well characterized, and how they are coordinated to
regulate HSPC localization relative to different components of
the niche is not known. Although previous work has provided
insight into the role of Rho GTPases Rac1, Rac2 (13, 14), and
Cdc42 (15) in HSPC trafﬁcking and engraftment (reviewed in
ref. 16), cells deﬁcient in these GTPases show multiple pro-
liferative, survival, and cytoskeletal defects, which precluded a
more precise dissection of the key pathways regulating HSPC
trafﬁcking and localization. Thus, Rac-deﬁcient HSPC show re-
duced chemotaxis to SDF1α and β1 integrin-mediated adhesion
in vitro but also defects in SCF-mediated proliferation and sur-
vival (14), consistent with the integration of multiple receptors
and signaling pathways. In vivo, Rac1 is required for HSPC en-
graftment and endosteal localization in the BM, whereas de-
letion of both Rac1 and Rac2 not only impairs engraftment
but causes massive HSPC mobilization (13, 14). Dissecting this
complex regulation involves deﬁning the functional interactions
between GTPases and speciﬁc guanine nucleotide exchange
factors (GEFs) that activate them (17), and this remains a major
challenge.
Here we focus on the Vav subfamily of GEFs, which consists
of three related proteins: Vav1 (hematopoietic-speciﬁc) and Vav2
and Vav3 (more broadly expressed) (18). Vav proteins have non-
redundant functions in lymphopoiesis related to their role in
immunoreceptor signaling. Thus, Vav1
−/− mice show defective T
and B-1 cell development (19–21), whereas mutation of all three
Vav genes completely impairs both the B- and T-lymphoid lin-
eages (22). In neutrophils, Vav proteins are required for sus-
tained β2 integrin-mediated adhesion, intravascular endothelial
crawling, and superoxide production (23–25). Despite the well-
characterized function of Vav proteins in immune processes,
virtually nothing is known about the role of these GEFs in
primitive hematopoietic cells. We hypothesized that the hema-
topoietic-speciﬁc GEF Vav1 may regulate HSPC engraftment
and retention by mediating responses to a subset of microenvi-
ronmental signals.
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on HSPC homing, localization, and retention in the BM micro-
environment, and the role of Vav1 in mediating HSPC responses
to chemokine and adhesion ligands. Our results suggest that Vav1
activity is required speciﬁcally for SDF1α-dependent perivascular
homing of HSPC and suggest a critical role for this localization in
BM retention and subsequent engraftment.
Results
Dysregulated Rho GTPase Activation in Vav1
−/− Hematopoietic Pro-
genitors. We reasoned that, if Vav1 is a biologically relevant and
nonredundant GEF in HSPC, deletion of Vav1 in this cellular
compartment would induce alterations in Rho GTPase activa-
tion. In addition, Vav1 itself would be expected to be activated
by factors present in the BM microenvironment. Vav1 was rap-
idly phosphorylated in WT hematopoietic progenitors in re-
sponse to in vitro stimulation by SCF/SDF1α (Fig. 1A Upper).
Whereas Vav1
−/− cells did not show any agonist-induced tyrosine
phosphorylation, a cross-reactive band was observed in non-
stimulated Vav1
−/− cells. As Vav1 protein was absent from
Vav1
−/− immunoprecipitates (Fig. 1A Lower), this suggested a
compensatory, abnormal increase in the activation of another
Vav protein. Indeed, increased baseline phosphorylation of Vav3
was detected with a phosphospeciﬁc antibody in Vav1
−/− pro-
genitors (Fig. 1B).
We observed two distinct abnormalities in hematopoietic
progenitors isolated from the BM of Vav1
−/− mice. First, the
baseline levels of GTP-bound (active) Rac and Cdc42 were un-
expectedly elevated, which is consistent with the dysregulated
activation of either or both Vav2 and Vav3. The total level of
Rac and Cdc42 proteins was also increased, compared with WT
progenitors (Fig. 1C). Second, in the absence of Vav1, both Rac
and Cdc42 were unresponsive to in vitro stimulation by the
combination of SCF and SDF1α, known critical regulators of
HSPC engraftment and activators of Rac and Cdc42 GTPases in
HSPC (13–15) (Fig. 1C). To determine whether these changes
were physiologically relevant, we studied known downstream
targets of Rac which we have previously demonstrated to be
involved in HSPC homing and retention (13, 14, 26, 27). Vav1
−/−
progenitors showed increased baseline activation of the Rac/
Cdc42 effector p21-activated kinase (PAK) and reduced activa-
tion of PAK after SCF/SDF1α stimulation (Fig. 1D). There were
no measurable changes in other kinase signaling pathways, in-
cluding ERK, JNK, and AKT (Fig. 1D). These results suggested
that Vav1 may function as a critical signaling molecule regulating
HSPC functions.
Abnormal Responses to SDF1α in Vav1
−/− HSPC. The BM of Vav1
−/−
mice contained normal numbers of immunophenotypically de-
ﬁned long-term HSC, modestly increased frequency of short-
term HSC, and slightly reduced numbers of common myeloid
progenitors and granulocyte-monocyte progenitors as deﬁned by
surface markers (Fig. S1A). However, the frequency of func-
tionally deﬁned myeloid progenitors in the BM, as determined
by in vitro growth in methylcellulose, was similar to that of WT
mice; we did not observe any alterations in the number of colony-
forming cells (CFC) obtained in the presence of SCF or
granulocyte-colony-stimulating factor (G-CSF) alone or multiple
cytokines, or in the frequency of high-proliferation potential
colony-forming cells (HPP-CFC), which represent more primi-
tive progenitors (Fig. S1B). Moreover, the frequency of cobble-
stone area-forming cells (CAFC) in Vav1
−/− BM was virtually
identical to that of WT mice both at early (reﬂecting mature
progenitors) and late (representing more primitive HSPC) time
points (Fig. S1C). Consistent with these data, analysis of the cell
cycle (Fig. S1D) and apoptosis (Fig. S1E) of immunopheno-
typically deﬁned HSPC subsets in the BM of Vav1
−/− mice did
not reveal any alterations.
We have previously shown that deﬁciency of the Vav target
Rac is associated with massive mobilization of HSPC from the
BM. However, analysis of the number of progenitors in periph-
eral blood of Vav1
−/− mice unexpectedly revealed signiﬁcantly
decreased numbers of circulating CFC and absence of circadian
variation (Fig. 2A). Because circadian ﬂuctuations in the numbers
of circulating HSPC inversely correlate with periodic changes in
SDF1α levels in the BM microenvironment (28), these data
suggested an abnormal response of Vav1
−/− HSPC to SDF1α.T o
test this hypothesis, we treated Vav1
−/− and WT mice with the
SDF1α receptor (CXCR4) antagonist AMD3100, known to in-
duce HSPC mobilization (29). AMD3100 mobilized only 55% of
the number of Vav1
−/− progenitors that the same treatment in-
duced in WT mice (739 vs. 407 CFC/mL, considering untreated
mice as baseline; Fig. 2B). G-CSF-induced progenitor mobiliza-
tion, which is mediated at least in part by SDF1α down-regulation
(30) or proteolytic degradation (31) in the BM, was also severely
impaired in Vav1
−/− mice (Fig. 2C). Thus, in the absence of Vav1,
HSPC are relatively insensitive to physiologic or induced changes
in SDF1α levels or activity in the BM in vivo.
SDF1α acts both as a chemoattractant, being the only che-
mokine known to be active on HSPC (32), and as a signal that
increases β1 integrin afﬁnity for ligand binding in different cell
types, including hematopoietic progenitors (“inside-out signal-
ing”) (33, 34). To dissect the requirement of Vav1 in SDF1α-
mediated HSPC functions, we studied the role of Vav1 in each of
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Fig. 1. Dysregulated Rho GTPase activation in Vav1
−/− he-
matopoietic progenitors. (A) Vav1 activation as demon-
strated by immunoprecipitation (IP) with a Vav1-speciﬁc
antibody, followed by detection with phosphotyrosine
(P-Tyr) antibody. WT or Vav1
−/− lineage-depleted cells were
starved in 1% FBS for 6 h and stimulated with SCF + SDF1α
(100 ng/mL each) for the indicated time points. WB, Western
blot. (B) Vav3 phosphorylation in WT and Vav1
−/− progeni-
tors, detected with a phosphospeciﬁca n t i b o d y .( C) Levels of
active (GTP-bound) and total Rac and Cdc42 in WT or Vav1
−/−
lineage-depleted cells. Cells were starved and stimulated
as in A. GTP-bound Rho GTPases were precipitated with
agarose-conjugated PAK1-p21-binding domain (PBD) and
detected by Western blot. (D) Activation status of different
signaling pathways in WT and Vav1
−/− progenitors, analyzed
by Western blot with phosphospeciﬁc antibodies. Lineage-
depleted cells were either freshly puriﬁed (B, baseline acti-
vation) or starved in 1% FBS for 6 h and then stimulated
with SCF + SDF1α (100 ng/mL each) for the indicated time
points. Arrows indicate phospho-Vav3 (B)a n dt h ed i f f e r e n t
isoforms of phospho-PAK and phospho-JNK (D).
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−/− lin
− Sca1
+ ckit
+ (LSK) cells
observed by time-lapse microscopy showed signiﬁcantly abnor-
mal migratory response to an SDF1α gradient (Fig. 2 D–F and
Movies S1 and S2). Compared with WT LSK cells, the distance
migrated by Vav1
−/− cells in 1 h (Fig. 2E) and their speed (Fig.
2F) were signiﬁcantly decreased. Absence of Vav1 did not affect
the directionality of cell migration. On the other hand, Vav1 was
not required for baseline or SDF1α-induced β1 integrin-mediated
adhesion, measured either as static adhesion to ﬁbronectin- or
VCAM1-coated plates (Fig. S2A) or as the resistance of adherent
cells to detachment from an immobilized β1 integrin ligand under
conditions of shear stress (Fig. S2B). SDF1α stimulation induced
β1 integrin-mediated ﬁrm adhesion of WT and Vav1
−/− progen-
itors to a similar extent, suggesting that deletion of Vav1 does
not affect SDF1α-mediated inside-out β1 integrin signaling (Fig.
S2B). Surface expression of β1 integrin subunits α4 and α5 was
similar in WT and Vav1
−/− LSK or lin
− ckit
+ Sca1
− cells (Fig.
S2C). Together, these data suggest that Vav1 mediates chemo-
tactic but not adhesive responses to SDF1α in HSPC.
Engraftment Defect of Vav1
−/− HSPC. SDF1α/CXCR4 signaling is
required for engraftment and retention of HSPC in the BM after
transplantation (8, 9, 35). To further study the role of Vav1 in
SDF1α responses in vivo, we determined whether Vav1
−/− HSPC
were able to engraft and reconstitute hematopoiesis. In initial
repopulation assays, WT and Vav1
−/− BM cells were transduced
withretroviral vectors encoding twodifferent ﬂuorescent proteins
and transplanted into isogenic recipients. In this experimental
setting, Vav1
−/− cells displayed dramatically reduced engraftment
ability (Fig. S3). This experiment was also performed with the
reverse color combination, with similar results. To eliminate
possible effectsofinvitromanipulationonengraftmentofVav1
−/−
cells, we performed competitive repopulation assays with freshly
isolated, unmanipulated cells. Vav1
−/− cells did not contribute
signiﬁcantly to donor chimerism in peripheral blood at any time
point after transplant (Fig. 3A), and were absent from BM and
spleen 4 mo posttransplant (Fig. 3B). All three lineages examined
(myeloid, B-lymphoid, and T-lymphoid) demonstrated defective
repopulation in mice transplanted with Vav1
−/− BM cells (Tables
S1 and S2). In contrast, WT BM cells showed stable chimerism
at a level consistent with the input (53.5–63.2%), arguing against
the possibility that the different genetic background of donor and
recipient mice (C57BL/10J versus C57BL/6J) may be responsible
for the engraftment failure of Vav1
−/− cells.
Vav1
−/− BM cells also performed poorly in noncompetitive
repopulation assays: A fraction of mice (4/10, 40%) transplanted
with Vav1
−/− BM in the absence of competitor cells died within
the ﬁrst month posttransplant, whereas all animals (10/10) re-
ceiving WT cells survived (Fig. 3C). Surviving mice engrafted
with Vav1
−/− BM showed signiﬁcantly delayed hematopoietic
reconstitution, compared with mice receiving WT cells (Fig. 3D).
Taken together, these data demonstrate a signiﬁcant defect
in the capacity of Vav1
−/− HSPC to engraft in transplant re-
constitution assays, despite the normal progenitor content and
even an elevated frequency of phenotypically deﬁned, short-term
HSC in the BM of Vav1
−/− mice. This phenotype is observed at
all time points analyzed, suggesting a defect common to both
short- and long-term repopulating cells.
Vav1
−/− HSPC Show Abnormal Homing Toward Nestin
+ MSC. To gain
further mechanistic insight into this engraftment defect, we
studied the role of Vav1 in HSPC homing and microlocalization
in the BM. Vav1
−/− HSPC showed normal homing efﬁciency as
determined by CFC assay at 16 h (Fig. 4A) and by intravital
microscopy of 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbo-
cyanine perchlorate (DiD)-labeled LSK cells 1 h posttransplant
(Fig. 4B). Therefore, Vav1 is not required for initial homing of
HSPC into the BM cavity. Because SDF1α is expressed at
highest levels by perivascular nestin
+ MSC (6) and at lower
levels by other cell populations including osteoblasts (5, 36, 37),
we directly visualized the homing of DiD-labeled WT or Vav1
−/−
LSK cells to deﬁned regions of the calvarium BM using intravital
microscopy (7). The use of two transgenic reporter mouse
strains, Nestin-GFP and Col2.3-GFP, allowed the study of HSPC
localization with respect to perivascular nestin
+ MSC and oste-
oblastic cells, respectively.
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Fig. 2. Abnormal SDF1α responses in Vav1
−/− HSPC. (A) Day–night variation in the number of CFC in peripheral blood of WT and Vav1
−/− mice. Blood was
collected 4 or 16 h after the onset of light. Data represent mean ± SD, n =4 –6; *P < 0.05 (t test). NS, nonsigniﬁcant. (B) Numbers of CFC in peripheral blood of
WT and Vav1
−/− mice, either untreated or treated with 5 mg/kg of AMD3100 for 1 h. Data represent mean ± SD, n =6 –7; *P < 0.05 (t test). (C) Numbers of CFC
in peripheral blood of WT and Vav1
−/− mice, either untreated or treated with G-CSF at a daily dose of 200 μg/kg for 6 d. Data represent mean ± SD, n =3 ;* P <
0.05, **P < 0.005 (t test). The graph shows one of two experiments that yielded similar results. (D–F) In vitro chemotaxis of WT or Vav1
−/− LSK cells on a
ﬁbronectin-coated coverslip in the presence of an SDF1α gradient, determined by time-lapse microscopy. (D) Paths followed by individual cells in 1 h. Rep-
resentative ﬁelds (325 × 325 μm) from one out of three similar experiments are shown. (E) Net path length migrated in 1 h (mean ± SEM, n =3 6 –38 cells per
genotype) and (F) speed of migration (mean ± SEM, n =1 4 –41). For E and F, one representative experiment of a total of three is shown. **P < 0.005 (t test).
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−/− HSPC localized signiﬁ-
cantly farther from nestin
+ cells 1 h after transplant. Only 6.25%
of Vav1
−/− HSPC, compared with 45.8% of WT HSPC, were
located less than 30 μm from a nestin
+ cell (n =2 4 –32 HSPC
analyzed). In addition, 25% of Vav1
−/− HSPC versus only 8.3%
of WT HSPC were found in microscopic ﬁelds (330 × 330 μm)
lacking nestin
+ cells. Considering only WT and Vav1
−/− HSPC
with nestin
+ cells in their proximity, the mean distance of HSPC
to the nearest nestin
+ cell was signiﬁcantly shorter for WT versus
Vav1
−/− HSPC (WT, 39.54 ± 6.91 μm; Vav1
−/−, 65.24 ± 5.22 μm;
n =2 2 –24; P = 0.005) (Fig. 4C and Fig. S4). In contrast, the
distribution of Vav1
−/− HSPC relative to osteoblasts (Fig. 4D and
Fig. S4) and endosteal surface (Fig. 4E) 1 h after transplant was
not signiﬁcantly different from that of WT HSPC (n =7 7 –98
HSPC analyzed).
Impaired Retention of Vav1
−/− HSPC in the BM Niche. To assess re-
tention of transplanted HSPC in the BM, we examined by in-
travital microscopy the number and localization of DiD-labeled
LSK cells present in the calvarium BM cavity at 48 h post-
transplant. Contrary to the earlier time point, the total number
of Vav1
−/− LSK cells in the BM cavity at 48 h was signiﬁcantly
decreased, compared with WT cells in both Nestin-GFP and
Col2.3-GFP recipients (60% and 44% reduction, respectively;
P < 0.05 for both strains, for a total of three to ﬁve recipient mice
analyzed per strain and genotype; Fig. 5A), suggesting impaired
retention. At this time point, there was not any signiﬁcant dif-
ference in the localization of retained Vav1
−/− HSPC with respect
to nestin
+ cells, osteoblasts, or endosteal surface, compared with
WT HSPC (Fig. 5 B–D). We attempted to determine whether
this reduction in the number of donor cells in the BM correlated
with their increase in circulation; however, the numbers of cir-
culating donor cells detected at this time point (<0.25% donor
chimerism in peripheral blood 48 h after transplant of 1.5 × 10
5
lin
− ckit
+ cells, for both genotypes) was too low to allow any
conclusions.
Although Vav1
−/− HSPC did not demonstrate any alteration in
proliferation or apoptosis (Fig. S1D and E) in primary mice
during homeostatic hematopoiesis, it was still possible that
defects in the proliferation or survival of these cells following
transplantation—rather than reduced retention—could account
for the reduced numbers of Vav1
−/− HSPC observed at the 48 h
imaging time point. To determine the proliferation status of
transplanted hematopoietic progenitors shortly after the initial
BM homing, we injected WT or Vav1
−/− lin
− ckit
+ cells into le-
thally irradiated recipients, which were pulsed with BrdU 48 h
after transplant. There was no signiﬁcant difference in the frac-
tion of donor-derived (CD45.2
+) BM cells incorporating BrdU
between the two genotypes (45.8 ± 6.10% vs. 50.5 ± 5.8%, WT vs.
Vav1
−/−, n =5 –6 mice per genotype; Fig. S5A). An independent
measure of HSPC proliferation after transplant was obtained
from in vivo imaging experiments, in which the presence of
clusters of DiD
+ cells with a reduction in dye intensity can be
taken as an indication of proliferation of single transplanted
cells (7). The fraction of proliferating LSK cells, as determined
by the percentage of cell clusters 48 h after transplant, was similar
for WT and Vav1
−/− cells (38.0 ± 12.4% vs. 42.9 ± 14.2%, WT vs.
Vav1
−/−, n =4 –5 mice per genotype; Fig. S5B), consistent with
the BrdU-labeling studies. Likewise, the fraction of lin
− ckit
+
cells that were apoptotic (Annexin V
+) 48 h after transplant was
not signiﬁcantly different between the two genotypes (Fig. S5C).
These data are consistent with normal ERK, JNK, and AKT ac-
tivation previously noted (Fig. 1B) and support the hypothesis
that the failure of Vav1
−/− cells to engraft is due to reduced re-
tention in the BM. Taken together, these data imply that Vav1 is
required in HSPC for a normal response to SDF1α leading to
Rac/Cdc42 activation, perivascular localization, retention in the
BM niche, and engraftment.
Discussion
Previous work has demonstrated that Rho GTPases function as
central molecules critical for the interaction of HSPC with the
BM hematopoietic microenvironment. Inactivation of Rac1 alone
0
20
40
60
80
100 WT
Vav1-/-
d
o
n
o
r
-
d
e
r
i
v
e
d
 
c
e
l
l
s
 
(
%
)
0
5
10
15
20
14 28 60
WT
Vav1-/-
0
10
20
30
40
50
60
70
80
90
012345
WT
Vav1-/-
* * * *
months after transplant BM Spleen
0
20
40
60
80
100
120
01 0 2 0 3 0 4 0
WT
Vav1-/-
days after transplant days after transplant
A B
CD
d
o
n
o
r
-
d
e
r
i
v
e
d
 
c
e
l
l
s
 
(
%
)
s
u
r
v
i
v
a
l
 
(
%
)
W
B
C
 
/
 
µ
l
 
o
f
 
b
l
o
o
d
 
(
x
1
0
3
)
*
*
*
*
Fig. 3. Engraftment defect of Vav1
−/− BM cells. (A) Peripheral blood chi-
merism of lethally irradiated B6.SJL (CD45.1) mice transplanted with 3 × 10
6
WT or Vav1
−/− (CD45.2) BM cells and an equal number of WT CD45.1 BM cells
as competitors. (B) CD45.2 chimerism in BM and spleen for the recipient mice
in A, killed 4 mo posttransplant. Data in A and B are expressed as the per-
centage of CD45.2
+ cells in the nucleated fractions measured by ﬂow
cytometry. Mean ± SD, n =5 ,* P < 0.005 (t test). Note: Chimerism for Vav1
−/−
cells in BM and spleen was less than 2%. (C) Survival of lethally irradiated B6.
SJL mice transplanted with 3 × 10
6 WT or Vav1
−/− (CD45.2) BM cells in the
absence of competitor cells; n = 10 mice per genotype. (D) Leukocyte counts
in peripheral blood of the recipient mice in C surviving at each time point.
Mean ± SD, n =6 –10, *P < 0.005 (t test).
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Fig. 4. Bone marrow homing and localization of Vav1
−/− HSPC. (A) Homing
efﬁciency of WT and Vav1
−/− progenitors (CFC) to the BM of C57BL/10J
recipients 16 h after transplant. Data represent mean ± SD, n =5 .( B) Number
of DiD
+ LSK cells detected by intravital microscopy in a 4 × 6 mm region of
the calvarium of Col2.3-GFP mice 1 h after transplant, for an input of 30,000
LSK cells (mean ± SD, n = 3). (C–E) Distances (in μm) of transplanted LSK cells
to nestin
+ cells (C), osteoblastic cells (D), and endosteal surface (E)i nt h e
calvarium of Nestin-GFP (C) or Col2.3-GFP (D and E) mice, determined 1 h
after transplant. Data represent measurements for individual LSK cells;
horizontal lines represent the mean. C represents pooled data from three
mice per genotype (n =2 4 –32); D and E represent data from one repre-
sentative mouse per genotype, out of three analyzed (n =3 2 –34; total
number of events analyzed, n =7 7 –98). *P = 0.005 (t test).
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Rac2 (13, 14) or Cdc42 (15) leads to massive egress of HSPC
from the BM. Rac and Cdc42 are activated by multiple receptors
via a large family of Rho GEFs, of which ∼70 members have
been described so far (17). Thus, genetic studies examining the
phenotype of Rho GTPase knockouts, even when performed in
a lineage-speciﬁc fashion, likely demonstrate the combinatorial
effects of multiple receptors and downstream signaling pathways.
Indeed, one of the challenges in understanding the speciﬁc roles
of chemokine and adhesion receptors in HSPC function is that
many downstream GEFs may activate multiple Rho GTPases in
an apparently redundant and cell- or agonist-speciﬁc fashion.
Here we have demonstrated a role for Vav1 as a key func-
tional regulator of Rac/Cdc42 in HSPC, as shown by the fact that
deletion of this single GEF completely alters Rho GTPase ac-
tivation patterns in hematopoietic progenitors. Vav1
−/− progen-
itors show defective activation of Rac and Cdc42 and their
effector PAK in response to SDF1α and SCF, agonists previously
shown to activate Rac in HSPC and critical in HSPC engraft-
ment. Unexpectedly, however, Vav1
−/− progenitors also showed
baseline hyperactivation of Rac and Cdc42, probably due to
compensatory hyperactivation of Vav2/Vav3.
Although Vav- and Rac-deﬁcient HSPC exhibit similar en-
graftment defects in repopulation assays, their phenotypes are
in most other respects remarkably different, allowing a more
precise dissection of the critical pathways regulating HSPC
trafﬁcking and interaction with the hematopoietic micro-
environment. Whereas Rac-deﬁcient HSPC show alterations in
multiple cellular processes involved in engraftment and retention
(SCF-induced proliferation, chemotaxis, homing, survival, and β1
integrin-mediated adhesion), the engraftment failure of Vav1
−/−
HSPC appears to be speciﬁcally associated with a much more
restricted defect: abnormal response to SDF1α leading to ab-
normal localization and reduced retention, underscoring the key
role of this distinct pathway in HSPC engraftment. Interestingly,
the lack of postengraftment retention is not related to the ab-
sence of any immunophenotypically or in vitro deﬁned HSPC
population in Vav1
−/− mice, suggesting that signaling pathways
are qualitatively or quantitatively differentially used in post-
transplant versus ontogenic migration and expansion of HSPC.
On the other hand, Vav1
−/− and Rac1
−/−;Rac2
−/− mice unex-
pectedly show opposite mobilization phenotypes, with decreased
versus highly increased numbers of circulating progenitors, re-
spectively. The ﬁndings that both Vav1
−/− and Rac1
−/− HSPC,
which have normal β1 integrin-mediated adhesion, do not show
increased mobilization, whereas Rac2
−/− and Rac1
−/−;Rac2
−/−
HSPC mobilize in inverse correlation to their decreased binding
to ﬁbronectin, imply that HSPC mobilization may be more de-
pendent on loss of integrin-mediated adhesion than on migration
per se, at least as measured by in vitro assays.
These data also suggest that different Rho GEFs play selective
roles downstream of different extracellular signals, thus con-
trolling distinct cellular processes. Thus, inactivation of other
GEFs expressed in HSPC leads to phenotypes strikingly different
from Vav1
−/−. Similar to combined genetic deletion of Rac1 and
Rac2, pharmacologic inhibition of Tiam1/Trio-mediated Rac
activation by NSC23766 induces HSPC mobilization (13), sug-
gesting that these GEFs may be required for integrin-mediated
Rac activation and HSPC adhesion. Conversely, deletion of
Vav1, which is not targeted by NSC23766 (38), does not affect
adhesion nor induce mobilization but leads to defective SDF1α
responses.
Vav1 is required for appropriate HSPC responses to SDF1α
under both physiologic conditions and in the posttransplant he-
matopoietic microenvironment. Thus, Vav1
−/− HSPC showed
impaired in vitro chemotaxis; reduced mobilization induced by
AMD3100 or G-CSF (both of which depend on CXCR4/SDF1α
inactivation); absence of physiologic, circadian mobilization
[related to oscillations in SDF1α levels in the BM (28)]; and
reduced homing to the proximity of SDF1α-expressing nestin
+
MSC, recently implicated as perivascular cells that contribute to
the HSC niche and are required for HSC maintenance (6). These
observations delineate a speciﬁc requirement for Vav1 in the
proposed role of the CXCR4/SDF1α axis in the regulation of
HSPC trafﬁcking and engraftment. Although initial data showed
that homing of HSPC is blocked by anti-CXCR4 antibodies (39),
subsequent studies found that Cxcr4
−/− progenitors home nor-
mally (8), which is consistent with our ﬁndings in Vav1
−/− cells.
Taken together, these studies suggest that this pathway is dis-
pensable for the initial BM homing. However, CXCR4 signaling
is required for the engraftment and retention of human HSPC in
non-obese diabetic (NOD)/SCID mice (9), and murine Cxcr4
−/−
HSPC show reduced retention in the BM microenvironment
after transplantation (8, 35), which parallels our observations
with Vav1
−/− HSPC. Together, these data support the idea that
the initial bone marrow homing and subsequent retention are
two components of the engraftment process with distinct bio-
chemical regulation.
Vav1
−/− HSPC appear to retain partial responsiveness to an
SDF1α gradient, being able to migrate short distances and being
mobilized at lower levels by AMD3100. Vav2 and Vav3, which
have been shown to play both unique and overlapping roles in
lymphocytes, may play partially compensatory roles in some of
the migratory and adhesive functions of HSPC, which may allow
the retention of Vav1
−/− HSPC under steady-state conditions but
may not be sufﬁcient under the more stringent conditions of a
BM transplant. Vav3 (and possibly Vav2) is hyperactivated in
unstimulated Vav1
−/− progenitors (Fig. 1B).
The defect in early localization of Vav1
−/− HSPC near nestin
+
MSC correlates with impaired BM retention and engraftment. In
contrast, correct positioning of Vav1
−/− HSPC with respect to
osteoblastic cells or the matrix of the endosteal surface was not
sufﬁcient for functional engraftment. These data do not rule out
a role for the osteoblastic space in long-term HSPC mainte-
nance; however, they support the idea that localization in the
proximity of a perivascular mesenchymal cell is required in the
initial stages of HSPC homing and is important for their early
retention. Nestin
+ MSC are major producers of SDF1α in the
BM (6), and we have shown that Vav1 is required for appropriate
responses of HSPC to SDF1α, consistent with the abnormal lo-
calization of Vav1
−/− HSPC in the perivascular, SDF1α-abundant
space. Thus, we describe a signaling pathway differentially reg-
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Fig. 5. Reduced retention of Vav1
−/− HSPC in the BM. (A) Number of DiD
+
LSK cells detected by intravital microscopy in a 4 × 6 mm region of the cal-
varium of Nestin-GFP and Col2.3-GFP mice 48 h after transplant (mean ± SD,
n =4 –5) for an input of 30,000 LSK cells. *P < 0.05 (t test). (B–D) Distances (in
μm) of transplanted LSK cells to nestin
+ cells (B), osteoblastic cells (C), and
endosteal surface (D) in the calvarium of Nestin-GFP (B) or Col2.3-GFP (C and
D) mice, determined 48 h after transplant. Data represent measurements for
individual LSK cells; horizontal lines represent the mean. B represents pooled
data from three mice per genotype (n =2 9 –71); C and D represent data from
one representative mouse per genotype, out of three analyzed (n =3 8 –59;
total number of events analyzed, n = 102–139).
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Sulating HSPC localization with respect to perivascular versus
osteoblastic niche components.
Together, our data imply that the hematopoietic-speciﬁc GEF
Vav1 is essential for the correct response of HSPC to SDF1α in
the BM microenvironment, leading to Rac/Cdc42 activation,
perivascular localization, retention in the BM niche, and sub-
sequent engraftment, and deﬁne a critical biochemical pathway
in the regulation of Rho GTPase activity in HSPC.
Methods
Mice. All procedures involving mice followed Children’s Hospital Boston In-
stitutional Animal Care and Use Committee guidelines. Vav1
−/− mice have
been previously reported (20) and were backcrossed into a C57BL/10J
(CD45.2) background. Age- (8- to 16-wk-old) and sex-matched C57BL/10J
mice (Jackson Laboratory) were used as WT controls. B6.SJL (CD45.1) mice
(Jackson Laboratory) were used as recipients in some transplant assays. All
recipient mice were lethally irradiated (
137Cs source, 11.5-Gy whole-body
irradiation) before BM transplant.
Transplants, Progenitor Assays, and Flow Cytometry. Hematopoietic repopu-
lationabilitywasassessedinbothcompetitiveandnoncompetitiveassays(see
SI Methods for details). Progenitor content in BM and peripheral blood was
determined by methylcellulose CFC assays, as previously described (13, 14).
Thefrequencyofcirculating HSPCwas determinedunderdifferentconditions
(diurnal vs. nocturnal, AMD3100, G-CSF). In vivo HSPC proliferation and ap-
optosis were determined by BrdU incorporation and Annexin V binding
assays (BD Biosciences), respectively, either in primary, unmanipulated mice
or in transplanted lin
− ckit
+ cells 48 h posttransplant. Biochemical assays,
immunophenotyping, and progenitor homing assays were performed es-
sentially as described elsewhere (13, 14).
Chemotaxis and Adhesion Assays. In vitro migration in response to SDF1α was
measured by time-lapse microscopy in Dunn chemotaxis chambers, as de-
scribed (14) (see also SI Methods). Static adhesion assays were performed as
previously described (13, 14). Firm adhesion and the effect of SDF1α on
adhesion were measured with a computer-operated ﬂow-chamber device
(Mirus Nanopump; Cellix; SI Methods).
Intravital Microscopy. HSPC microlocalization in the BM was analyzed by in-
travital microscopy using previously described equipment and procedures (7).
The use of two transgenic reporter mouse strains, nestin-GFP and Col2.3-GFP,
allowed the study of HSPC localization with respect to perivascular nestin
+
MSC and osteoblastic cells, respectively. Cells were imaged at two time points
posttransplant, 1 h (to determine the initial homing and localization) and
48 h (to assess short-term retention and the effect of proliferation as de-
termined by clusters of DiD
+ cells with generally reduced dye intensity).
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SI Methods
Mice. All protocols were approved by the Children’s Hospital
Boston Institutional Animal Care and Use Committee. Age- and
sex-matched Vav1
−/− (1) and wild-type (WT) C57BL/10J mice
(Jackson Laboratory) were used between 8 and 16 wk of age. B6.
SJL (CD45.1) mice (Jackson Laboratory) were used as recipients
in competitive transplant assays. B6.SJL and C57BL/10J carry
identical major histocompatibility complex haplotypes (http://
www.jax.org/phenome), and WT C57BL/10J BM cells stably en-
graft B6.SJL recipients (Fig. 3). All recipients were lethally ir-
radiated (
137Cs source, 11.5-Gy whole-body irradiation, split dose
7.5 + 4.0 Gy, 3 h apart) before bone marrow (BM) transplant.
Biochemical Assays. Rac/Cdc42 activation assays were performed
on lineage-depleted cells (either freshly isolated or starved for 6 h
in Iscove’s modiﬁed Dulbecco’s medium (IMDM), 1% FBS, and
then stimulated as required) as previously described (2).
For the detection of Vav1 phosphorylation, 1 × 10
6 lin
− cells
were lysed in 20 mM Tris HCl (pH 8), 150 mM NaCl, 10%
glycerol, 1% Triton X-100, 2 mM EDTA, 10 mM NaF, 1 mM
Na3VO4, and Complete protease inhibitors (Roche). Lysates
were incubated with 2 μg of Vav1 antibody (B6; Santa Cruz
Biotechnology) overnight at 4 °C. After addition of 40 μLo f
protein A/G-agarose (Santa Cruz Biotechnology), lysates were
incubated for another 4 h at 4 °C. The beads were washed ﬁve
times in lysis buffer and boiled in 2× Laemmli sample buffer, and
the bound fractions were analyzed by immunoblot.
For immunoblot, the following primary antibodies were used
at a 1:1,000 dilution except where otherwise indicated: Rac (clone
102) and Cdc42 (clone 44), from BD Biosciences; Vav1 (2502),
phospho-PAK1/2/3 (Ser199/204), phospho-p44/p42 MAPK
(Thr202/Tyr204;197G2),phospho-JNK(Thr183/Tyr185),phospho-
p38 (Thr180/Tyr182; 28B10), phospho-AKT (Ser473), from Cell
Signaling Technology; phosphotyrosine (4G10) from Millipore;
phospho-Vav3, from BioSource; and β-actin (AC-15; 1:10,000
dilution) from Sigma.
Flow Cytometry. Bones (femora, tibiae, and iliac crests) were
crushed in a mortar, and single-cell suspensions were prepared
from WT and Vav1
−/− mice. Red blood cells were lysed by in-
cubationinBDPharmLyse(BDBiosciences)for10min.Cells(1–
2×10
6cellspersample)wereincubated witha1:100dilution(2–5
μg/mL) of ﬂuorescent antibody conjugates and 4′,6-diamidino-2-
phenylindole (DAPI) (0.2 μg/mL; Sigma) for dead cell exclusion,
and analyzed on an LSR II ﬂow cytometer (BD Biosciences). The
following antibody conjugates were used: CD45.1-FITC (A20),
CD45.2-phycoerythrin (PE) (104), c-kit-APC (2B8), Flk2-PE
(A2F10.1), CD49d-FITC (R1-2), CD49e-PE (5H10-27), and bi-
otinylated or PE-conjugated CD11b (M1/70), Gr-1 (RB6-8C5),
Ter119, B220 (RA3-6B2), CD3ε (145-2C11), CD4 (GK1.5), and
CD8a (53-6.7), from BD Biosciences; and FITC- or PE-Cy5.5-
conjugated Sca-1 (D7), CD34-FITC (RAM34), CD16/32-Paciﬁc
blue (93), IL7Rα-PE-Cy7 (A7R34), from eBioscience. Bio-
tinylated antibodies were detected with streptavidin-APC-Cy7
(BD Biosciences). Phenotypic populations of hematopoietic stem
and progenitor cells (HSPC) were deﬁned according to the fol-
lowing scheme: long-term hematopoietic stem cells (HSC) [lin
−
Sca1
+ ckit
+ (LSK) CD34
− Flk2
−], short-term HSC (LSK CD34
+
Flk2
−), multipotential progenitors (MPP) (LSK CD34
+ Flk2
+),
common myeloid progenitors (CMP) (lin
− Sca1
− ckit
+ CD34
+
FcγRIII/II
−), granulocytic-monocytic progenitors (GMP) (lin
−
Sca1
− ckit
+ CD34
+ FcγRIII/II
+), and megakaryocytic-erythroid
progenitors (MEP) (lin
− Sca1
− ckit
+ CD34
− FcγRIII/II
−).
Cell-Cycle and Apoptosis Analysis in Vivo. For the determination of
cell-cycle status in immunophenotypically deﬁned HSPC, mice
were injected intraperitoneally with 1 mg of 5-bromo-2′-deoxy-
uridine (BrdU) (BD Biosciences) and killed 4 h later. BM cells
were ﬁrst incubated with surface antibodies (lin, ckit, Sca1,
CD34, Flk2), then ﬁxed, permeabilized, and stained using the
APC BrdU Flow Kit (BD Biosciences), following the manu-
facturer’s instructions. To determine apoptosis levels, BM cells
were ﬁrst stained with surface antibodies and then with Annexin
V-APC (BD Biosciences) and DAPI (0.2 μg/mL).
For the analysis of proliferation and apoptosis of transplanted
HSPC, 1.5 × 10
5 WT or Vav1
−/− lin
− ckit
+ cells were injected into
B6.SJL recipients. Mice were treated with 1 mg BrdU 48 h post-
transplant and killed 12 h later. Red cell-lysed BM cells were in-
cubated with CD45.1-FITC and CD45.2-PE antibodies, and then
either ﬁxed and stained with anti-BrdU to determine their cell-
cyclestatusorstainedwithAnnexinV-APCand7-aminoactinomycin
D to measure apoptosis levels.
Colony-Forming Cell and Cobblestone Area-Forming Cell Assays.
Methylcellulose colony-forming cell (CFC) assays and high-
proliferation potential (HPP)-CFC were performed as previously
described (2). Limiting-dilution cobblestone area-forming cell
(CAFC) assays were performed on FBMD-1 stromal cells as
described elsewhere (2, 3) and the frequency of CAFC was
calculated by Poisson statistics using L-Calc software (StemCell
Technologies).
Mobilization Assays. Untreated mice were bled at 4 and 16 h after
the onset of light to determine circadian variations in circulating
CFC. HSPC mobilization was induced with AMD3100 octahy-
drochloride hydrate (Sigma) (5 mg/kg for 1 h, s.c.) or rhG-CSF
(Amgen) (daily dose of 200 μg/kg for 6 d, i.p.). CBC counts were
obtained using a Hemavet 950 analyzer (Drew Scientiﬁc). After
red cell lysis, peripheral blood cells were plated in methylcellu-
lose for determination of progenitor content as described above.
In Vitro Chemotaxis Assays. In vitro chemotaxis in response to
stromal derived factor-1 alpha (SDF1α) was analyzed by time-
lapse microscopy as previously described (4). Approximately
50,000 LSK cells were plated for 1 h on a ﬁbronectin-coated glass
coverslip, which was then placed in a Dunn chemotaxis chamber
(Hawksley). SDF1α (100 ng/mL) was added as a chemoattractant
in the outer well, and cells were imaged for 1 h at 30-s intervals
using an Eclipse Ti microscope and NIS-Elements software
(Nikon). Cell tracking and calculations of distance, speed, and
directionality were performed with DIAS 3.0 software (Soll
Technologies).
In Vitro Adhesion Assays. To determine static adhesion of hema-
topoietic progenitors to different substrates in vitro, low-density
bone marrow cells (300,000 cells per well) in complete medium
were plated in triplicate on 24-well non-tissue culture-treated
plates previously coated with ﬁbronectin (CH-296, 30 μg/mL;
Takara Bio) or VCAM1-Fc (20 μg/mL; R&D Systems). Cells
were incubated for 1 h at 37 °C, after which the supernatant was
removed and the wells were washed once with PBS to remove
nonadherent cells. Adherent cells were harvested by treatment
with Cell Dissociation Buffer, enzyme-free (Invitrogen) and plated
in methylcellulose. Progenitor adhesion was determined as the
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frequency of CFC in the input sample.
Resistance of integrin-mediated adhesion to shear stress was
measured using Vena8 biochips connected to a Mirus Nanopump
syringe pump (Cellix). Biochips were coated with VCAM1-Fc (1
μg/mL) and SDF1α (10 μg/mL), or with VCAM1-Fc alone. Lin
−
ckit
+ cells (100,000 per well) were injected into one of the mi-
crocapillaries of the biochip, allowed to adhere statically for 5
min at 37 °C, and then subjected to increasing shear stress rates
(1–15 dyne/cm
2) in 1-min segments. The biochip was imaged by
time-lapse microscopy, and the number of adherent cells at the
end of each ﬂow rate segment was determined using ImageJ
software (http://rsbweb.nih.gov/ij).
Competitive and Noncompetitive Repopulation Assays. WT and
Vav1
−/− BM cells harvested from 5-ﬂuorouracil-treated mice
(150 mg/kg, i.v.) were transduced with retroviral vectors encod-
ing EGFP and Venus, respectively (SF-IRES-GFP, SF-IRES-
Venus) (5). Equal numbers of sorted EGFP
+ WT and Venus
+
Vav1
−/− cells (3 × 10
5 cells per genotype and recipient) were
mixed and transplanted into C57BL/10J mice together with 1 ×
10
6 nontransduced C57BL/10J BM competitor cells. An in-
dependent experiment performed with the reverse color com-
bination (Venus-WT and EGFP-Vav1
−/−) yielded similar results
(data not shown). In additional competitive repopulation assays,
freshly isolated WT or Vav1
−/− BM cells (3 × 10
6 nucleated cells
per recipient) were mixed with 3 × 10
6 B6.SJL cells and trans-
planted into B6.SJL mice. Recipients were bled monthly and
killed 4 mo after transplant for the analysis of long-term BM and
spleen engraftment; chimerism was assessed by ﬂow cytometry.
For noncompetitive repopulation assays, WT or Vav1
−/− BM
cells (3 × 10
6 nucleated cells per recipient) were transplanted
into B6.SJL recipients. Mice were monitored for survival and
bled at different time points to assess peripheral blood counts.
Progenitor Homing Assays. Progenitor homing was measured es-
sentially as described (2). Brieﬂy, 1.5 × 10
7 WT or Vav1
−/− nu-
cleated BM cells were injected into lethally irradiated C57BL/
10J mice. Femora were harvested 16 h posttransplant. Homing
efﬁciency was calculated as the CFC frequency in recipient BM
relative to that in the input BM sample. For the estimation of
BM homing efﬁciency, it was assumed that one femur represents
∼6% of the total BM content of the mouse (6).
Intravital Microscopy. HSPC microlocalization in the BM was
analyzed by intravital microscopy using previously described
equipment and procedures (7). Thirty thousand LSK cells were
labeled with 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbo-
cyanine perchlorate (DiD) (Invitrogen) and injected into Nestin-
GFP (8) or Col2.3-GFP (9) transgenic mice. A deﬁned region of
calvarium BM cavity (4 × 6 mm) was scanned using a confocal/
two-photon hybrid microscope as previously described (7), al-
lowing visualization of DiD
+ HSPC, EGFP
+ mesenchymal stem
cells (MSC), or osteoblastic cells and endosteal matrix (collagen
visualized by second-harmonic generation microscopy). Imaging
was performed at 1 and 48 h posttransplant; three to ﬁve re-
cipient mice were analyzed per recipient strain, time point, and
genotype. For each DiD
+ cell identiﬁed, a Z stack was acquired.
Distances were measured manually for each image in the Z
stack, using ImageJ software (http://rsbweb.nih.gov/ij), and the
shortest 3D distance was calculated. Cells were imaged at two
time points posttransplant, 1 h (to determine the initial homing
and localization) and 48 h (to assess short-term retention and the
effect of proliferation as determined by clusters of DiD
+ cells
with generally reduced dye intensity). Three to ﬁve recipient
mice were analyzed per strain, time point, and donor genotype.
Statistical Analysis. Datasets were compared by two-tailed t tests;
P values less than 0.05 were considered statistically signiﬁcant.
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Sanchez-Aguilera et al. www.pnas.org/cgi/content/short/1102018108 2o f7Fig. S1. Characterization of primitive hematopoietic cell populations in Vav1
−/− mice. (A) Cell numbers (×10
6) in immunophenotypically deﬁned HSPC subsets
in the BM of WT and Vav1
−/− mice, as determined by multiparameter ﬂow cytometry. Cell populations were deﬁned as explained in Methods. Data represent
mean ± SD, n =7 ,* P < 0.05 (t test). (B) Number (×10
3) of CFC in the BM of WT and Vav1
−/− mice obtained in the presence of single or multiple cytokines; n =7
(HPP-CFU), n = 4 (all others). (C) Frequency of CAFC in WT or Vav1
−/− BM. The x axis represents weeks in culture; the y axis represents the number of CAFC per
100,000 BM cells at each time point, determined by limiting dilution. (D) Fraction of BM cells in S phase after a 4-h pulse of BrdU in WT and Vav1
−/− mice (n =4 ) .
Cells were gated on immunophenotypically deﬁned subsets. (E) Fraction of apoptotic (Annexin V
+ DAPI
−) cells in immunophenotypically deﬁned HSPC subsets
in the BM of WT and Vav1
−/− mice (n = 4). LT, long-term; ST, short-term; CMP, common myeloid progenitors; GMP, granulocytic-monocytic progenitors; MEP,
megakaryocytic-erythroid progenitors; MPP, multipotential progenitors.
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−/− BM cells. (A) Peripheral blood chimerism of lethally irradiated C57BL/10J mice transplanted with 3 × 10
5 WT (EGFP
+),
3 × 10
5 Vav1
−/− (Venus
+), and 1 × 10
6 nontransduced WT BM cells. (B) Chimerism in BM and spleen for the recipient mice in A, killed 4 mo after transplant. Data
represent the percentage of EGFP
+ (WT) and Venus
+ (Vav1
−/−) cells in the nucleated fractions, determined by ﬂow cytometry. Mean ± SD; n =7 ,* P < 0.01, **P <
0.001 (t test).
Fig. S2. Normal β1 integrin-mediated adhesion of Vav1
−/− progenitors. (A) Adhesion of WT or Vav1
−/− progenitors to ﬁbronectin (CH296)- or VCAM1-coated
plates, expressed as the percentage of input CFC that stably adhered to the plate in 1 h. Data represent mean ± SD of triplicate wells. Shown is one repre-
sentative experiment of a total of three that yielded similar results. (B) Firm adhesion of WT and Vav1
−/− lin
− c-kit
+ cells to VCAM1-coated microcapillaries
under conditions of shear stress, expressed as the percentage of input cells that remain attached to the substrate after application of increasing ﬂow rates.
Each value of shear stress force, as indicated in the graph, was applied for 1 min. Data represent mean ± SD, n =3 –7. (C) Membrane expression of CD49d (α4)
and CD49e (α5) integrin subunits in lin
− Sca-1
+ c-kit
+ (LSK) or lin
− Sca-1
− c-kit
+ (LK) cells, determined by ﬂow cytometry of WT and Vav1
−/− BM cells. MFI, mean
ﬂuorescence intensity. n = 4 mice per genotype.
Sanchez-Aguilera et al. www.pnas.org/cgi/content/short/1102018108 4o f7Fig. S4. Analysis of HSPC localization by intravital microscopy. Representative images of DiD-labeled WT or Vav1
−/− LSK cells 1 h after transplant into Nestin-
GFP or Col2.3-GFP mice, obtained by in vivo microscopy. Red, DiD (LSK cells); green, EGFP [nestin
+ MSC (Upper) or osteoblastic cells (Lower)]; blue, bone
(collagen visualized by second-harmonic generation microscopy). Microscopic ﬁelds are 330 × 330 μm. (Scale bars, 100 μm.)
Fig. S5. Analysis of proliferation and apoptosis of transplanted HSPC. (A) Fraction of WT or Vav1
−/− lin
− c-kit
+ cells incorporating BrdU in the BM of lethally
irradiated B6.SJL recipients. A 12-h BrdU pulse was given 48 h after transplant as described in Methods. Cells were gated on CD45.2 (donor-derived). Mean ± SD,
n =5 –6. NS, nonsigniﬁcant. (B) Fraction of clusters of ≥2D i D
+ LSK cells 48 h after transplant observed by intravital microscopy. Mean ± SD, n =3 –4 recipients per
genotype. (C) Fraction of WT or Vav1
−/− CD45.2
+ lin
− c-kit
+ cells that were Annexin V
+ 48 h after transplant into irradiated CD45.1 recipients. Mean ± SD, n =3 –4.
Table S1. Engraftment defect of Vav1
−/− HSPC: Lineage reconstitution
Peripheralblood[timeaftertransplant(mo)]
1 4 Bone marrow Spleen
CD11b
+ WT 15.68 ± 0.42 11.16 ± 4.37 40.50 ± 22.85 2.05 ± 1.28
Vav1
−/− 3.23 ± 0.94 0.022 ± 0.032 0.14 ± 0.20 0.021 ± 0.031
B220
+ WT 35.93 ± 0.64 35.51 ± 13.71 13.94 ± 5.55 42.49 ± 10.57
Vav1
−/− 4.14 ± 1.41 0.10 ± 0.16 0.56 ± 0.69 0.32 ± 0.32
CD3
+ WT 0.57 ± 0.65 2.80 ± 0.53 0.82 ± 0.20 6.49 ± 3.11
Vav1
−/− 0.006 ± 0.014 0.010 ± 0.013 0.04 ± 0.07 0.067 ± 0.082
Lineage reconstitution at 1 and 4 mo, for the competitive transplant shown in Fig. 3 A and B, expressed as percentage of CD45.2
+ cells relative to all viable
white blood cells. Shown are data for myeloid (CD11b
+), B-lymphoid (B220
+), and T-lymphoid (CD3
+) lineages. Bone marrow and spleen were analyzed 4 mo
posttransplant. Data represent mean ± SD, n =5 ;P < 0.05 for all WT versus Vav1
−/− comparisons.
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−/− HSPC: Lineage reconstitution
Peripheral blood [time after transplant (mo)]
1 2 3 4 Bone marrow Spleen
CD11b
+ WT 6.00 ± 2.59 4.73 ± 2.73 3.74 ± 1.99 4.72 ± 1.24 3.88 ± 2.06 0.47 ± 0.16
Vav1
−/− 1.17 ± 0.44 0.23 ± 0.29 0.18 ± 0.18 0.23 ± 0.17 0.34 ± 0.17 0.09 ± 0.05
B220
+ WT 25.56 ± 2.48 10.75 ± 1.56 9.01 ± 2.43 11.54 ± 6.11 1.94 ± 0.36 4.47 ± 0.96
Vav1
−/− 5.69 ± 2.91 0.80 ± 0.48 0.86 ± 0.90 0.80 ± 0.85 0.27 ± 0.25 0.54 ± 0.50
CD3
+ WT 1.57 ± 0.32 1.46 ± 0.27 2.58 ± 1.24 0.57 ± 0.43 2.32 ± 1.13
Vav1
−/− 0.04 ± 0.04 0.04 ± 0.02 0.10 ± 0.05 0.13 ± 0.04 0.17 ± 0.07
Lineage reconstitution at 1–4 mo, for the competitive transplant shown in Fig. S3, expressed as percentage of EGFP+ (WT) or Venus+ (Vav1
−/−) cells, relative
to all viable white blood cells. Shown are data for myeloid (CD11b+), B-lymphoid (B220+), and T-lymphoid (CD3+) lineages. Bone marrow and spleen were
analyzed 4 mo posttransplant. Data represent mean ± SD, n = 5–7; P < 0.05 for all WT versus Vav1
−/− comparisons.
Movie S1. Migration of WT LSK cells adhered on a ﬁbronectin-coated coverslip, subjected to an SDF1α gradient in a Dunn chemotaxis chamber and imaged by
time-lapse microscopy (2 frames/min for 1 h). Field dimensions are 227.5 × 227.5 μm.
Movie S1
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−/− LSK cells adhered on a ﬁbronectin-coated coverslip, subjected to an SDF1α gradient in a Dunn chemotaxis chamber and
imaged by time-lapse microscopy (2 frames/min for 1 h). Field dimensions are 227.5 × 227.5 μm.
Movie S2
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